Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Mevo Health

CoreAge Rx
Graded #1

Higher grade

vs+31.599999999999994
Mevo Health
Graded #326

Lower grade

The verdict

CoreAge Rx takes it — 91.8/100 to 60.2/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +36
92
56
Dose & formulationCoreAge Rx +5
88
83
Clinical oversightCoreAge Rx +26
93
67
Labs & monitoringCoreAge Rx +38
90
52
FulfillmentCoreAge Rx +38
95
57
Contract termsCoreAge Rx +76
96
20
CoreAge Rx · left barMevo Health · right bar

The numbers

MetricCoreAge RxMevo Health
WeighScore91.8/10060.2/100
GradeA−C
Scorecard rank#1#326
Semaglutide$149/mo$199/mo (all doses, compounded)
Tirzepatide$349/mo$259/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard